文献速递主动脉疾病

编辑推荐——新型即用型预装内分支覆膜支架治疗复杂主动脉病变的早期结局:意大利E-nside覆膜支架分支注册研究(INBREED)

Editor's Choice - Early Outcomes of a Novel Off the Shelf Preloaded Inner Branch Endograft for the Treatment of Complex Aortic Pathologies in the ItaliaN Branched Registry of E-nside EnDograft (INBREED).
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-03-03

本研究基于意大利多中心前瞻性注册研究,纳入31个中心116例使用E-nside即用型预装内分支胸腹主动脉覆膜支架治疗的主动脉病变患者,评估90天早期结局。技术成功率98.2%,90天死亡率为5.2%(择期修复2.1%,急诊修复16%),90天累积主要不良事件率为24.1%。作者认为该支架技术植入安全有效,但需更长期随访以明确其临床角色。

要点

  • E-nside即用型预装内分支覆膜支架治疗复杂主动脉病变技术成功率达98.2%。
  • 90天死亡率为5.2%,其中择期修复为2.1%,急诊修复为16%。
  • 90天累积主要不良事件率为24.1%,靶血管相关事件发生率为2.3%。

核心结论

  • 在真实世界非赞助注册研究中,E-nside覆膜支架用于治疗包括急诊病例和不同解剖形态在内的广泛主动脉病变,结果显示优异的技術植入安全性和有效性以及早期结局,但需更长期随访以更好定义该新型覆膜支架的临床角色。

研究设计与样本

  • 医师发起的全国多中心注册研究,前瞻性收集并分析使用E-nside覆膜支架治疗的患者数据,来自31个意大利中心,共纳入116例患者。
  • 术前临床和解剖特征、手术数据及早期结局(90天)记录于专用电子数据采集系统,主要终点为技术成功,次要终点包括90天早期死亡、手术指标、靶血管通畅率、内漏率和主要不良事件(MAEs)。

主要发现

  • 患者平均年龄73±8岁,男性76例(65.5%);主动脉病变包括退行性动脉瘤98例(84.5%)、夹层后动脉瘤5例(4.3%)、假性动脉瘤6例(5.2%)、穿透性主动脉溃疡或壁内血肿4例(3.4%)、亚急性夹层3例(2.6%)。
  • 平均动脉瘤直径66±17 mm;动脉瘤范围Crawford I-III型55例(50.4%)、IV型21例(19.2%)、肾旁型29例(26.7%)、近肾型4例(3.7%);急诊手术25例(21.5%)。
  • 中位手术时间240分钟(IQR 195, 303),中位造影剂用量175 mL(IQR 120, 235)。
  • 技术成功率98.2%,90天死亡率为5.2%(n=6;择期修复2.1%,急诊修复16%),90天累积MAE率为24.1%(n=28)。
  • 90天时靶血管相关事件10例(2.3%),包括9例闭塞和1例IC型内漏;1例1A型内漏需再干预。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长期随访以更好定义该新型覆膜支架的临床角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the early outcomes of a novel off the shelf pre-loaded inner branched thoraco-abdominal endograft (E-nside) in the treatment of aortic pathologies. METHODS: Data from a physician initiated national multicentre registry on patients treated with the E-nside endograft, were prospectively collected and analysed. Pre-operative clinical and anatomical characteristics, procedural data, and early outcomes (90 days) were recorded in a dedicated electronic data capture system. The primary endpoint was technical success. Secondary endpoints were early mortality (90 days), procedural metrics, target vessel patency, endoleak rate, and major adverse events (MAEs) at 90 days. RESULTS: In total, 116 patients from 31 Italian centres were included. Mean ± standard deviation (SD) patient age was 73 ± 8 years and 76 (65.5%) were male. Aortic pathologies included degenerative aneurysm in 98 (84.5%), post-dissection aneurysm in five (4.3%), pseudoaneurysm in six (5.2%), penetrating aortic ulcer or intramural haematoma in four (3.4%), and subacute dissection in three (2.6%). Mean ± SD aneurysm diameter was 66 ± 17 mm; aneurysm extent was Crawford I - III in 55 (50.4%), IV in 21 (19.2%), pararenal in 29 (26.7%), and juxtarenal in four (3.7%). The procedure setting was urgent in 25 (21.5%) patients. Median procedural time was 240 minutes (interquartile range [IQR] 195, 303), with a median contrast volume of 175 mL (IQR 120, 235). The endograft's technical success rate was 98.2% and the 90 day mortality rate was 5.2% (n = 6; 2.1% for elective repair and 16% for urgent repair). The 90-days cumulative MAE rate was 24.1% (n = 28). At 90 days, there were 10 (2.3%) target vessel related events (nine occlusions and one type IC endoleak) and one type 1A endoleak requiring re-intervention. CONCLUSION: In this real life, non-sponsored registry, the E-nside endograft was used for the treatment of a broad spectrum of aortic pathologies, including urgent cases and different anatomies. The results showed excellent technical implantation safety and efficacy, as well as early outcomes. Longer term follow up is needed to better define the clinical role of this novel endograft.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Piazza M, Squizzato F, Pratesi G, et al. Editor's Choice - Early Outcomes of a Novel Off the Shelf Preloaded Inner Branch Endograft for the Treatment of Complex Aortic Pathologies in the ItaliaN Branched Registry of E-nside EnDograft (INBREED). Eur J Vasc Endovasc Surg. 2023. PMID: 36871927. doi:10.1016/j.ejvs.2023.02.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。